-
Mashup Score: 49Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies - 2 month(s) ago
Off-the-shelf T-cell-redirecting bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 have high activity in multiple myeloma with a manageable toxicity profile. However, not all patients respond to bispecific antibodies and patients can develop bispecific antibody resistance after an initial response. Mechanisms that contribute to bispecific antibody resistance are multifactorial and include tumour-related factors, such as high tumour burden, expression of T-cell inhibitory ligands, and antigen loss.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms - 2 month(s) ago
Key PointsUDs transplant with PTCY for myelodysplastic neoplasms may improve OS and PFS as compared with ATG.PTCY may also decrease the incidence of grade
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms - 2 month(s) ago
Key PointsUDs transplant with PTCY for myelodysplastic neoplasms may improve OS and PFS as compared with ATG.PTCY may also decrease the incidence of grade
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old - 2 month(s) ago
The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted inc
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients - 2 month(s) ago
Key PointsAllogeneic hematopoietic cell transplant recipients are at risk of clinically significant viral infections due to lack of T-cell immunity.The mul
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience - 2 month(s) ago
Key PointsThe safety and efficacy benefits of ide-cel were proportionate in young and older patients despite frailty and geriatric characteristics.Treatmen
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Anti-CD37 CAR T cells: another arrow in the quiver - 2 month(s) ago
In this issue of Blood, Frigault et al1 describe the first-in-human trial of anti-CD37 chimeric antigen receptor (CAR) T cells in patients with refractory
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses - 2 month(s) ago
Key Points. With longer follow-up, significantly longer median PFS was maintained with ide-cel vs standard regimens (SRs); safety remained consistentOS ana
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation - 2 month(s) ago
Key PointsThis trial used a class I–restricted TCR and a CD8 coreceptor to enable antigen–specific CD8+ and CD4+ T-cell function.Primary end points of feas
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies #mmsm @TheLancetHaem @mvmateos @AjaiChari https://t.co/GeP4vF6Smf